We suggest that an increase in putrescine levels is one of the leading mechanisms underlying the acquisition of erlotinib resistance in human pancreatic cancers, and thereby propose that targeting ODC, a key enzyme in the polyamine pathway, might be a novel strategy for overcoming resistance to erlotinib. The gene discussed is ODC1; the disease is familial pancreatic carcinoma.